Missing the gorilla, focussing on the bounces
What if pharma teams would be incentivised to apply a different, asymmetric learning approach to create value for patients, prescribers, payers and return on invention vs being incentivised for getting an asset from one phase to the next...
Possible Punchline: "All they <told> us to do, was to count the bounces!"
What if pharma teams would be incentivised to apply a different, asymmetric learning approach to create value for patients, prescribers, payers and return on invention vs being incentivised for getting an asset from one phase to the next...
Possible Punchline: "All they <told> us to do, was to count the bounces!"